Urinary estrogen metabolites and their ratio among Asian American women

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 1, 2005, Pages 221-226

  Falk, Roni T ^a   Fears, Thomas R ^a   Xu, Xia ^a   Hoover, Robert N ^a   Pike, Malcolm C ^b   Wu, Anna H ^b   Nomura, Abraham M Y ^c   Kolonel, Laurence N ^c   West, Dee W ^d   Sepkovic, Daniel W ^e   Bradlow, H Leon ^e   Ziegler, Regina G ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^d NORTHERN CALIFORNIA CANCER CENTER   (United States)

^e HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

16ALPHA HYDROXYESTRONE; 2 HYDROXYESTRONE; ESTROGEN; TUMOR MARKER;

ADULT; ARTICLE; ASIAN AMERICAN; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DEMOGRAPHY; ESTROGEN METABOLISM; ESTROGEN URINE LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MIGRATION; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL;

ADULT; ANALYSIS OF VARIANCE; ASIAN AMERICANS; BREAST NEOPLASMS; CALIFORNIA; CASE-CONTROL STUDIES; CHINA; ESTROGENS; FEMALE; HUMANS; INTERVIEWS; JAPAN; MIDDLE AGED; PHILIPPINES; RISK FACTORS;

EID: 19944430571     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Yager JD, Liehr JG. Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol 1996;36:203-32.
2. Osborne MP, Bradlow HL, Wong GYC, Telang NT. Upregulation of estradiol C16α-hydroxylation in human breast tissue: a potential biomarker of breast cancer risk. J Natl Cancer Inst 1993;85:1917-20.
3. Telang NT, Axelrod DM, Bradlow HL. Metabolic biotransformation of estradiol in human mammary explant cultures. Ann N Y Acad Sci 1990; 586:70-8.
4. Bradlow HL, Hershcopf R, Martucci C, Fishman J. 16α-Hydroxylation of estradiol: a possible risk marker for breast cancer. Ann N Y Acad Sci 1986; 464:1338-51.
5. Schneider J, Kinne D, Fracchia A, et al. Abnormal oxidative metabolism of estradiol in women with breast cancer. Proc Natl Acad Sci U S A 1982; 79:3047-51.
6. Fishman J, Osborne MP, Telang NT. The role of estrogen in mammary carcinogenesis. Ann N Y Acad Sci 1995;768:91-100.
7. Schneider J, Huh MM, Bradlow HL, Fishman J. Antiestrogen action of 2-hydroxyestrone on MCF-7 human breast cancer cells. J Biol Chem 1984; 259:4840-5.
8. Martucci CP, Fishman J. Impact of continuously administered catechol estrogens in uterine growth and luteinizing hormone secretion. Endocrinology 1979;105:1288-92.
9. Vandewalle B, Lefebvre J. Opposite effects of estrogen and catechol estrogen on hormone-sensitive breast cancer cell growth and differentiation. Mol Cell Endocrinol 1989;61:239-46.
10. Key TJ, Pike MC. The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol 1988;24:29-43.
11. Kabat GC, Chang CJ, Sparano JA, et al. Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 1997; 6:505-9.
12. Zheng W, Dunning L, Jin F, Holtzman J. Correspondence re: Kabat GC, et al. Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 1997;7:85-6.
13. Coker AL, Crane MM, Sticca RP, Sepkovic DW. Re: Ethnic differences in estrogen metabolism in healthy women. J Natl Cancer Inst 1997;89:89-90.
14. Ho GH, Luo XW, Ji CY, Foo SC, Ng EH. Urinary 2/16α-hydroxyestrone ratio: correlation with serum insulin-tike growth factor binding protein-3 and a potential biomarker of breast cancer risk. Ann Acad Med Singapore 1998;27:294-9.
15. Muti P, Bradlow HL, Micheli A, et al. Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16α-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology 2000;11:635-40.
16. Meilahn EN, De Stavola B, Allen DS, et al. Do urinary oestrogen metabolites predict cancer? Guernsey III cohort follow-up. Br J Cancer 1998;78:1250-5.
17. Ursin G, London S, Stanczyk FZ, et al. Urinary 2-hydroxyestrone/ 16α-hydroxyestrone ratio and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1999;91:1067-72.
18. Adlercreutz H, Gorbach SL, Goldin BR, Woods MN, Dwyer JT, Hamalainen E. Estrogen metabolism and excretion in Oriental and Caucasian women. J Natl Cancer Inst 1994;86:1076-82.
19. Lemon HM, Rodriguez-Sierra JF. Re: Ethnic differences in estrogen metabolism in healthy women. J Natl Cancer Inst 1997;89:1626-8.
20. Jernstrom J, Klug T, Sepkovic DW, Bradlow HL, Narod SA. Predictors of the plasma ratio of 2-hydroxyestrone to 16α-hydroxyestrone among premenopausal, nulliparous women from four ethnic groups. Carcinogenesis 2003; 24:991-1005.
21. Taioli E, Garte SJ, Trachman J, et al. Ethnic differences in estrogen metabolism in healthy women. J Natl Cancer Inst 1996;88:617.
22. Ursin G, Wilson M, Henderson BE, et al. Do urinary estrogen metabolites reflect the differences in breast cancer risk between Singapore Chinese and U.S. African American and White women? Cancer Res 2001;61:3326-9.
23. Ziegler RG, Hoover RN, Pike MC, et al. Migration patterns and breast cancer risk in Asian-American women. J Natl Cancer Inst 1993;85:1819-27.
24. Falk RT, Fears TR, Hoover RN, et al. Does place of birth influence endogenous hormone levels in Asian-American women? Br J Cancer 2002; 87:54-60.
25. Falk RT, Rossi SC, Fears TR, et al. A new ELISA kit for measuring urinary 2-hydroxyestrone, 16α-hydroxyestrone, and their ratio: reproducibility, validity, and assay performance after freeze-thaw cycling and preservation by boric acid. Cancer Epidemiol Biomarkers Prev 2001;9:81-7.
26. Flores OR, Sun L, Vaziri ND, Miyada DS. Colorimetric rate method for the determination of creatinine as implemented by the Beckman creatinine analyzer 2. Am J Med Technol 1980;46:792-8.
27. Wilkinson L. SYSTAT: the system for statistics. Evanston (IL): SYSTAT, Inc.; 1986.
28. Snow RC, Barbieri RL, Frisch RE. Estrogen 2-hydroxylase oxidation and menstrual function among elite oarswomen. J Clin Endocrinol Metab 1989; 69:369-76.
29. De Cree C, Ball P, Seidlitz B, Van Kranenburg G, Geurten P, Keizer HA. Effects of a training program on resting plasma 2-hydroxycatecholestrogen levels in eumenorrheic women. J Appl Physiol 1997;83:1551-6.
30. Lu LW, Cree M, Josyula S, Nagamani M, Grady JJ, Anderson KE. Increased urinary excretion of 2-hydroxyestrone but not 16α-hydroxyestrone in premenopausal women during a soya diet containing isoflavones. Cancer Res 2000;60:1299-305.
31. Michnovicz JJ, Naganuma H, Hershcopf RJ, Bradlow HL, Fishman J. Increased urinary catechol estrogen excretion in female smokers. Steroids 1988;52:69-83.
32. Bradlow HL, Sepkovic DW, Telang NT, Osborne MP. Indole-3-carbinol. A novel approach to breast cancer prevention. Ann N Y Acad Sci 1995; 68:180-200.
33. Fowke JH, Longcope C, Hebert JR. Brassica vegetable consumption shifts estrogen metabolism in healthy postmenopausal women. Cancer Epidemiol Biomarkers Prev 2000;9:773-9.
34. Pasagian-Macaulay A, Meilahn EN, Bradlow HL, et al. Urinary markers of estrogen metabolism 2- and 16α-hydroxylation in premenopausal women. Steroids 1996;61:461-7.
35. Westerlind KC, Gibson KJ, Wolfe P. The effect of diurnal and menstrual cyclicity and menopausal status on estrogen metabolites: implications for disease-risk assessment. Steroids 1999;64:233-43.
36. Chen Z, Zheng W, Dunning LM, Anderson KG, Parrish RS, Holtzman JL. Within-person variability of the ratios of urinary 2-hydroxyestrone to 16α-hydroxyestrone in Caucasian women. Steroids 1999;64:856-9.
37. Bradlow HL, Telang NY, Sepkovic DW, Osborne MP. 2-Hydroxyestrone: the "good" estrogen. J Endocrinol 1996;150:S259-65.
38. Liehr JG. Dual role of oestrogens as hormones and pro-carcinogens: rumour initiation by metabolic activation of oestrogens. Eur J Cancer Prev 1997;6:3-10.
39. Badawi AF, Cavalieri EL, Rogan EG. Role of human cytochrome P450 1A1, 1A2, 1B1, and 3A4 in the 2-, 4-, and 16α-hydroxylauon of 17β-estradiol. Metabolism 2001;50:1001-3.